FDA Approves Lilly ' s Insulin Glargine Biosimilar, Rezvoglar FDA Approves Lilly ' s Insulin Glargine Biosimilar, Rezvoglar

Rezvoglar is the second"biosimilar" and the third off-brand version of the long-acting analogue insulin, originally sold as Lantus.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Alert Source Type: news